|
Affiliation |
Hospital Neurosurgery |
Research Interests 【 display / non-display 】
-
nuclear medicine
-
glioma
-
molecular biology
-
脳神経外科
Graduating School 【 display / non-display 】
-
-2009.03
Akita University Faculty of Medicine Graduated
Graduate School 【 display / non-display 】
-
-2015.03
Akita University Graduate School, Division of Medicine Doctor's Course Completed
Studying abroad experiences 【 display / non-display 】
-
2015.11-2017.06
Germany Guest Researcher, Department of Neuropathology, Institute of Pathology, University Heidelberg
Campus Career 【 display / non-display 】
-
2023.04-Now
Akita University Hospital Neurosurgery Lecturer
-
2017.07-2023.03
Akita University Graduate School of Medicine Doctorial Course in Medicine Organ Function-Oriented Medicine Assistant Professor
External Career 【 display / non-display 】
-
2023.04
Akita University Graduate School of Medicine Department of Neurosurgery Assistant Professor
-
2017.07
Akita University Graduate Scholol of Medicine Department of Neurosurgery Assistant Professor
-
2015.11-2017.06
University Heidelberg Institute of Pathology, Department of Neuropathology Guest Researcher
Research Areas 【 display / non-display 】
-
Life Science / Neurosurgery / brain tumor
Research Career 【 display / non-display 】
-
Refinement of IDH-mutated glioma classification and grading
International Joint Research Projects
Periods of research：
2015.11-2017.10Classification of research form：International Collaboration
-
Diagnostic significance of amino acid tracers for evaluation of temozolomide therapy with interferon-beta and bevacizumab in temozolomide-resistant malignant glioma
Grant-in-Aid for Scientific Research
Periods of research：
2011.04-2015.03Classification of research form：Collaboration within Japan
Research Achievements 【 display / non-display 】
-
Takahiro Ono, Hayato Suzuki, Hiroshi Nanjo, Hiroaki Shimizu
Journal of neuro-oncology ( Journal of Neuro-Oncology ) 168 ( 3 ) 393 - 404 2024.05 [Refereed]
Research paper (journal)
PURPOSE: It remains unclear whether combining carmustine wafer (CW) implantation with the standard treatment for adult-type diffuse gliomas is safe and has a prognostic impact. This study aimed to investigate the prognostic value and safety of CW implantation. METHODS: Adult patients with IDH-wild-type and -mutant gliomas, grades 3-4 treated with surgical resection, radiotherapy, and temozolomide chemotherapy between 2013 and 2023 were surveyed. CWs were implanted except in cases of intraoperative wide ventricle opening or marked preoperative brain swelling. For survival analyses, a case-matched dataset based on propensity score matching (PSM), including multiple factors (patient background, diagnosis, and extent of resection) was generated. Progression-free survival (PFS), overall survival (OS), and frequency of complications of CW implantation (brain edema, infection, and cerebrospinal fluid leakage) were compared between the CW and non-use groups. RESULTS: In total, 127 patients (75 in the CW use group and 52 in the non-use group) were enrolled. Regardless of stratification, no significant differences in PFS and OS were observed between the CW use and non-use groups. The frequency of postoperative brain edema was significantly higher in the CW use group than in the non-use group. An adjusted dataset containing 41 patients in the CW use and nonuse groups was generated. Even after PSM, CW implantation had no prognostic effect. CONCLUSIONS: CW implantation with standard treatment demonstrated little beneficial effect for the present strategy of CW use.
-
Takahashi Yusuke, Ono Takahiro, Moroi Junta, Maruya Jun, Togashi Shuntaro, Abe Takatsugu, Nakae Hajime, Fujita Yasuo, Takahashi Shinichi, Shimizu Hiroaki
脳神経血管内治療 ( 日本脳神経血管内治療学会 ) advpub ( 0 ) 103 - 109 2024 [Refereed]
Research paper (journal)
<p><b>Objective:</b> Early intervention with mechanical thrombectomy (MT) is expected to improve the functional outcome in patients with large vessel occlusion (LVO); however, a method for the effective detection of these patients in a prehospital setting and early transport to MT-capable hospitals has not been established. This study aimed to analyze the clinical impact and diagnostic performance of the emergent large vessel occlusion (ELVO) screen and its influence on the transportation time.</p><p><b>Methods:</b> The emergency medical services (EMS) in one of the secondary medical areas in Akita, Japan, introduced a prehospital triage system employing an ELVO screen and a rotation system of three MT-capable hospitals on December 1, 2021. Patients who were transferred to each of the three hospitals involved in the rotation system according to a predefined priority list from December 2021 to November 2022 were included in the triage group. Patients who underwent MT in the three hospitals before the introduction of the triage system were assigned to the pre-triage group. We compared the transportation time parameters between the two groups and analyzed the performance of the ELVO screen for the diagnosis of LVOs. This study was approved by the institutional review boards of all three hospitals.</p><p><b>Results:</b> Time parameters were compared between the 37 and 42 patients who underwent MT and had detailed data in the triage (n = 351) and pre-triage (n = 43) groups, respectively. The time from door to puncture tended to decrease in the triage group in all hospitals, with one hospital showing a statistically significant shortening of 14 min (p = 0.018). In the triage group, 209 ELVO screen-positive patients were present, with 60 (28.7%) of these having LVO. The sensitivity, specificity, positive and negative predictive values, and area under the curve of the ELVO screen to detect LVO under the present triage system were 87.0%, 47.2%, 28.7%, 93.7%, and 0.671, respectively.</p><p><b>Conclusion:</b> The present study demonstrated that the introduction of a triage system may have shortened the time required for MT. ELVO screen may be considered a useful marker for screening LVO in prehospital settings in terms of the sensitivity and negative predictive value; however, further improvement may be necessary to reduce the rate of false positive results.</p>
-
SHIMIZU Hiroaki, ONO Takahiro, ABE Takatsugu, HOKARI Masaaki, EGASHIRA Yusuke, SHIMONAGA Koji, KAWANISHI Masahiko, NOMURA Kyoko, TAKAHASHI Yusuke
Neurologia medico-chirurgica ( 一般社団法人 日本脳神経外科学会 ) advpub ( 0 ) 80 - 89 2023 [Refereed]
Research paper (journal)
<p>Intracranial carotid artery dissection causing cerebral ischemia is a rare but important cause of cerebral infarction in children and adolescents. Although endovascular therapy has been reported to be effective, questions regarding the indications for intervention are yet to be addressed. Therefore, this study aimed to evaluate factors related to clinical outcomes through a nationwide survey. Overall, 35 neurosurgical centers reported patients within 2 weeks after ischemic onset due to intracranial carotid artery dissection causing cerebral ischemia treated between January 2015 and December 2020. Data on clinical and radiological findings were statistically analyzed. Twenty-eight patients met the inclusion criteria. The median age was 36 years (range, 7-59 years), without sex differences. Headache at onset was documented in 60.7% of the patients. Dissection findings were categorized into stenosis (71.4%) or occlusion (28.6%). Initial treatments, including various antithrombotic agent combinations in 23 (82.1%) patients, effectively improved or prevented aggravation in half of the patients. The patients with stenotic dissection were significantly more likely to experience aggravation during the initial treatment than did those with occlusive dissection (<i>P</i> = 0.03). In addition, the patients with moderate to severe neurological deficits on admission had poorer outcomes at discharge more frequently than did those with mild neurological deficits on admission. Eight patients undergoing endovascular therapy had no procedural complications or further aggravation after intervention. In conclusion, patients with intracranial carotid dissection causing cerebral ischemia who had a stenotic dissection were at risk of further aggravation, and endovascular therapy effectively improved or prevented aggravation.</p>
-
Takahiro Ono, Felix Hinz, Shogo Tanaka, Masataka Takahashi, Hiroshi Nanjo, Andreas von Deimling, Hiroaki Shimizu
Journal of Neurosurgery: Case Lessons ( Journal of Neurosurgery Publishing Group (JNSPG) ) 3 ( 14 ) 2022.04 [Refereed]
Research paper (journal)
BACKGROUND
Recent studies report that cerebellar glioblastoma (GBM) is categorized into the RTK1 methylation class. GBM pediatric RTK (pedRTK) subtypes are distinct from those of adult GBM. We present a unique adult case of cerebellar GBM classified into the pedRTK subtype.
OBSERVATIONS
Magnetic resonance imaging revealed a homogeneous enhancing lesion in the right cerebellum in a 56-year-old woman presenting with ataxia and dizziness. Arterial spin labeling and angiographic findings and the intraoperative orange-colored tumor appearance were reminiscent of hemangioblastoma. She showed an atypical presentation in terms of high glucose metabolism. The histological diagnosis was high-grade glioma with differentiation similar to central nervous system neuroblastoma. The methylation class was GBM pedRTK1. Consistent with this classification, immunoexpression was positive for SOX10 and negative for ANKRD55. She underwent craniospinal radiotherapy (23.4 Gy) with a boost to the tumor bed (total 55.8 Gy). Twelve courses of temozolomide therapy were administered. There was no recurrence 18 months after surgery.
LESSONS
Radiological and intraoperative findings, such as hemangioblastoma and high glucose metabolism, were notable characteristics in the present case. Both glial and neuronal differentiation and SOX10 immunoexpression were presenting pathological features. Similar cerebellar GBMs might form a previously unestablished subtype. Establishing effective molecular diagnoses is important. -
Oligosarcomas, IDH-mutant are distinct and aggressive
Suwala A.K.
Acta Neuropathologica ( Acta Neuropathologica ) 143 ( 2 ) 263 - 281 2022.02 [Refereed]
Research paper (journal)
Oligodendrogliomas are defined at the molecular level by the presence of an IDH mutation and codeletion of chromosomal arms 1p and 19q. In the past, case reports and small studies described gliomas with sarcomatous features arising from oligodendrogliomas, so called oligosarcomas. Here, we report a series of 24 IDH-mutant oligosarcomas from 23 patients forming a distinct methylation class. The tumors were recurrences from prior oligodendrogliomas or developed de novo. Precursor tumors of 12 oligosarcomas were histologically and molecularly indistinguishable from conventional oligodendrogliomas. Oligosarcoma tumor cells were embedded in a dense network of reticulin fibers, frequently showing p53 accumulation, positivity for SMA and CALD1, loss of OLIG2 and gain of H3K27 trimethylation (H3K27me3) as compared to primary lesions. In 5 oligosarcomas no 1p/19q codeletion was detectable, although it was present in the primary lesions. Copy number neutral LOH was determined as underlying mechanism. Oligosarcomas harbored an increased chromosomal copy number variation load with frequent CDKN2A/B deletions. Proteomic profiling demonstrated oligosarcomas to be highly distinct from conventional CNS WHO grade 3 oligodendrogliomas with consistent evidence for a smooth muscle differentiation. Expression of several tumor suppressors was reduced with NF1 being lost frequently. In contrast, oncogenic YAP1 was aberrantly overexpressed in oligosarcomas. Panel sequencing revealed mutations in NF1 and TP53 along with IDH1/2 and TERT promoter mutations. Survival of patients was significantly poorer for oligosarcomas as first recurrence than for grade 3 oligodendrogliomas as first recurrence. These results establish oligosarcomas as a distinct group of IDH-mutant gliomas differing from conventional oligodendrogliomas on the histologic, epigenetic, proteomic, molecular and clinical level. The diagnosis can be based on the combined presence of (a) sarcomatous histology, (b) IDH-mutation and (c) TERT promoter mutation and/or 1p/19q codeletion, or, in unresolved cases, on its characteristic DNA methylation profile.
-
Outcomes of initial conservative management in patients with acute subdural hematoma
Kuwayama Mikiko, Ono Takahiro, Togashi Shuntaro, Takahashi Masataka, Shimizu Hiroaki
Neurotraumatology ( The Japan Society of Neurotraumatology ) 46 ( 1 ) 12 - 19 2023.06 [Refereed]
-
Automation of novel rapid-immunohistochemistry (R-IHC)
南條博, 廣嶋優子, 今井一博, 寺田かおり, 小野隆裕, 中村竜太, 大久保義真, 赤上陽一, 南谷佳弘
日本病理学会会誌 110 ( 1 ) 2021
-
The REAL-WORLD of Elderly PCNSL Therapy in Tohoku and Niigata Area According to Retrospective Analysis: A Collaborative Investigation of the Tohoku Brain Tumor Study Group
浅野研一郎, 山下洋二, 小野隆裕, 棗田学, 別府高明, 松田憲一朗, 市川優寛, 金森政之, 松坂方士, 黒瀬顕, 齋藤清, 園田順彦, 小笠原邦昭, 藤井幸彦, 清水宏明, 大熊洋揮, 北中千史, 嘉山孝正, 冨永悌二
日本脳腫瘍学会プログラム・抄録集 38th 2020
-
Intracerebral hemorrhage: the role of surgery
鈴木隼士, 鈴木隼士, 小野隆裕, 山口卓, 西野克寛, 清水宏明
脳卒中 41 ( 1 ) 2019
-
Large Hypervascular Acoustic Tumor treated with Intravascular Embolization followed by Staged Resection : A Case Report
高橋和孝, 松本康史, 山口卓, 小野隆裕, 小田正哉, 笹嶋寿郎, 清水宏明
脳神経外科ジャーナル 24 ( 8 ) 2015 [Refereed]
◆Original paper【 display / non-display 】
◆Other【 display / non-display 】
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
Grant-in-Aid for Scientific Research(C)
Project Year： 2024.04 - 2029.03
-
Grant-in-Aid for Early-Career Scientists
Project Year： 2019.04 - 2023.03
-
Grant-in-Aid for Early-Career Scientists
Project Year： 2019.04 - 2023.03